ADARx Pharmaceuticals Raises $446.3 Million in Upsized US IPO
ADARx Pharmaceuticals raised $446.3 million in an upsized US initial public offering, pricing 26.3 million shares at $17 each, the top end of its marketed range. The San Diego-based biotech had initially planned to...
Electra Therapeutics Targets Up to $978 Million Valuation in U.S. IPO
Drug developer Electra Therapeutics is targeting a valuation of up to $977.6 million in its U.S. initial public offering, according to a filing on Monday, adding to a broader recovery in biotech listings this...
GSK to Invest £400 Million in UK R&D Expansion
British pharmaceutical company GSK announced a £400 million investment over the next three years to strengthen its UK operations, including relocating its research and development activities to a new Cambridge facility. The move is...
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk has filed a lawsuit against rival Eli Lilly in a U.S. federal court, accusing the American pharmaceutical company of misleading advertising by claiming its weight-loss drugs outperform Novo’s treatments. The lawsuit, filed...
FDA Panel to Review Moderna’s Flu Vaccine for Older Adults
The U.S. Food and Drug Administration’s (FDA) independent vaccine advisory panel is set to review and vote on whether the benefits of Moderna’s influenza vaccine, mFlusiva, outweigh its potential risks in older adults. Moderna...
Psychedelic Drug Stocks Surge After Trump Fast-Tracks Reviews and Funding
Shares of psychedelic drug developers rallied sharply in premarket trading on Monday after Donald Trump signed an executive order directing health regulators to accelerate the approval process for psychedelic-based treatments and increase federal research...